Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Looks To Jumpstart Cardiac Surgery Business; CHF Next

This article was originally published in The Gray Sheet

Executive Summary

St. Jude expects U.S. approval of the Biocor andEpic tissue valves to shore up its declining heart valve business. Launch of the Biocor stented tissue valve is anticipated in the first half of 2004

You may also be interested in...



SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business

St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003

SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business

St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003

Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%

Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel